Receptor.AI and Sethera Plan to Create Closed-Loop Discovery and Optimization Workflow for Difficult Therapeutic Targets
The collaboration is specifically focused on applying Receptor.AI's computational platform to Sethera's proprietary polymacrocyclic peptide chemistry, encoded screening data, and resulting therapeutic candidates. Each company will retain its background platform technologies. The post Receptor.AI and Sethera Plan to Create Closed-Loop Discovery and Optimization Workflow for Difficult Therapeutic…
Receptor.AI and Sethera have entered into a partnership to develop a closed-loop drug discovery workflow aimed at addressing difficult therapeutic targets. Sethera will generate and screen diverse polymacrocyclic peptide libraries through the installation of stable cross-links, while Receptor.AI will employ physics-based modeling, artificial intelligence, and multiparameter optimization to interpret data associated with sequence, architecture, enrichment, and activity.
This data will be utilized to formulate binding hypotheses, prioritize candidate series, and guide focused optimization cycles. The companies intend to enhance the potency, selectivity, stability, permeability, and other developability characteristics of identified hits. Following successful validation of the initial workflow, the collaboration intends to expand to internal programs and partnerships with pharmaceutical and biotechnology companies.
Both companies emphasize the importance of a closed feedback loop between experimentation and computational modeling to drive advancements in peptide lead discovery.
Written by urgent.news from GEN Biotechnology's reporting — not their text. Machine-written — it may contain errors, so check the original before relying on it.
